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n iNTRODUCTiON
Meningitis and or ventriculitis may be a sig-nificant complication in patients undergo-
ing craniotomy and the incidence is up to 8% in 
patients with external catheter derivation (EVD) 
[1, 2]. Coagulase-negative staphylococci are pre-
dominant amongst Gram-positive and, amongst 
Gram-negative rods, Acinetobacter baumannii has 
an incidence of 3.6-11% [3]. Risk factors for infec-
tion are represented by leakage of the cerebrospi-
nal fluid (CSF), concomitant infection at the time 
of incision, prolonged or repeated surgery and 
prolonged ventricular drainage, surgery through 
the sinuses as well as severity of underlying 
condition [4, 5]. Aetiology by pseudomonas and 
carbapenemase-producing Enterobacteriaceae is 
even more complex and difficult to treat [6-9].
The choice and kinetics of antimicrobials in cen-
tral nervous system (CNS) infections is of utmost 
importance and the blood-brain barrier (BBB) has 
specific features that limit the passage of mol-
ecules on several parameters such as size, lypo-
philia, plasma protein binding and transporter af-
finity [10]. In patients with acute bacterial menin-
gitis the CNS transfer of drugs may be increased 
due to opening of intracellular tight junctions, in-
creased CSF outflow resistance, low pH and also 
by transporters stimulated by proinflammatory 
cytokines. There is a poor CSF penetration of be-
ta-lactams (AUCCSF/AUCserum <0.15) that increases 
with inflammation, without requiring intraven-
tricular administration. Other antibiotics such as 
aminoglycosides, glycopeptides and polymyxins 
have a very low therapeutic index, with low CSF 
concentrations and therefore require lumbar, in-
trathecal or intraventricular (ITH/IVT) adminis-
tration; only the latter ensure distribution in the 
hole CSF space.
Pharmacokinetic of colistin 
Colistimethate (CSM) is eliminated by the kidneys 
and has a half-life of 2.7-4.5 hours; after a standard 
intravenous (IV) administration of 5 mg/Kg/day, 
the average plasma concentration is 8.1 mg/mL. 
The few data available on the pharmacokinetics 
of polymyxins in CSF reported a low diffusion 
through the CNS, with unclear rate of penetration 
and a possible role for meningeal inflammation 
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[11]. When colistin concentrations were measured 
by microbiological assay, the low CNS concentra-
tions were not enhanced by meningeal inflamma-
tion [12]. Methodological issues in studies before 
2009 may be responsible for the low concentration 
of both colistin and CMS, in a context in heteroge-
neous patient populations composed by children, 
adults, neurosurgical patients with EVD and vari-
able amount of daily CSF drainage, with or with-
out meningeal inflammation. Moreover, standard 
dosage of IV administration of colistin was not 
universally applied, as we did in a series of three 
patients [13, 14].
Jimenez Mejitas et al. reported CSF concentrations 
as high as 25% of serum concentration, with an IV 
infusion of 1,000,000 IU every 6 hours by a broth-
dilution assay of polymyxins, using Escherichia 
coli strain ATCC 25922, whilst Markantonis et al. 
used high-performance liquid chromatography 
(HPLC) in five non-consecutive critically ill adult 
patients receiving intravenous CMS at variable 
dosages from 150 mg daily to 225 mg three times 
a day (1,875,000-2,812,500 IU): three patients had 
meningitis without considerable meningeal in-
flammation [11, 15, 16]. Serum and CSF samples 
were collected after two days of treatment by 
lumbar puncture in four patients and from EVD 
in one patient, with a ratio of the area under the 
concentration-time curve (AUC) for CSF-serum of 
0.051. It is interesting that the AUC of colistin in 
CSF were parallel with simultaneous peaks and 
similar same half-life. According to these results, 
the conclusion was that the CSF penetration was 
only of 5%, consistently with previous studies 
performed by microbiological assays, suggest-
ing a low possibility of eradication of infections 
by Gram-negative bacteria [12]. Antachopulos 
et al. used liquid chromatography tandem mass 
spectrometry (LC-MS-MS) to study the CMS con-
centrations in three paediatric patients with EVD 
[17]. Intravenous colistin had low CSF concentra-
tions below 0.2 mcg/mL and higher (34% to 67% 
of sera concentrations) levels of colistin were ob-
served with meningeal inflammation.
According to these studies, IV colistin alone does 
not provide CSF concentrations high enough to 
reach a MIC of 2 mcg/mL for MDR Gram-neg-
ative rods and therefore topical administration is 
needed to support the treatment. Only two stud-
ies described the PK of ITH/IVT colistin: Imberti 
et al. studied by HPLC and by one-compartment 
model colistin CSF in nine patients only treated 
with IVT colistin at variable dosages, from 2.61 
to 10.44 mg (32,000-130,000 IU) [18]. The C-trough 
concentration ranged between 2,0 and 9,7 mcg/
mL and the CSF concentration were always >2 
mcg/mL when colistin was administered at a 
dose >65,200 IU/day, with a great inter-patients 
variability, perhaps due to the unknown fractions 
of CMS metabolized to colistin, the diffusion from 
the CSF to the systemic circulation and the cere-
bral tissue and the elimination through the ex-
ternal efflux of CSF, in addition to the unpredict-
able amount of the CSF spontaneously drained 
through the EVD by the fluctuation of intracra-
nial pressure. Therefore it is not surprising that 
the ITH/IVT dose of 125,000 IU/day suggested 
by the IDSA guidelines seems to be more appro-
priate [19]. 
Twelve patients treated with IVT-IV colistin 
(3,000,000 IU every 8 hours and IVT dose of 
125,000 IU daily) and EVD were studied by HPLC 
by Ziaka, of which five were treated only IV, three 
only by IVT administration and four patients by 
IVT-IV. The CSF concentrations in the IV group 
were very low, with a ratio of 0.07 [20]. There was 
no accumulation of colistin concentration over 
time, the mean CSF/serum concentration was 
higher in IVT-IV combination than in the other 
groups and the mean AUC CSF/AUC serum ra-
tios were 60% higher in patients with ventriculitis 
than in control patients. Perhaps a greater pen-
etration could be achieved with meningeal in-
flammation but a median CSF concentration >0.5 
mcg/mL was only observed in the combination 
group, suggesting that IV colistin could increase 
CSF concentrations of ITH/IVT colistin; the con-
clusion was that combined treatment had a better 
chance to eradicate severe CNS infections [20].
Clinical data
Intrathecal/Intraventricular (IVT/ITH) colistin 
administration was associated with better out-
comes compared to IV colistin alone [21-23]. 
There are guidelines available such as those by 
the Infectious Diseases Society of America (IDSA) 
in 2004 that suggested a daily ITH dosage of 10 
mg (125,000 IU) [19]. However, in clinical prac-
tice, the dose is often chosen empirically, ranging 
between 1.6 and 40 mg (20,000-500,000 IU) either 
as a single dose or in divided doses. We synthe-
tized in Table 1 the main data collected from all 
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Table 1 - Reported cases of Gram-negative CNS infections in adults treated with intrathecal or intraventricular 
colistin. Dosages reported in the original paper are converted in International Units (1 mg of colistin equals 30.000 
IU of colistin and 1 mg of colistimethate equals 12.500 IU of colistin). ITH: intrathecal, IVT: intraventricular, IV: intra-
venous, NR: not reported, qd: once daily, bid: twice a day.
Author,
year, reference Case no. Microorganisms
ITH, IVT Colistin dose (IU), 
timing, (days of treatment)
IV 
Colistin Other antibiotics
Infection 
outcome
Price, 1972 [24] 5 K. aerogenes IVT 50,000
bid à qd (NR)
Yes gentamicin 2/5 Cure
Kaplan, 1990 [25] 1 A. baumannii ITH NR (20) No cefotaxime,
aminoglycoside
Cure
Fernandez-
Viladrich, 1999 [26]
2 A. baumannii ITH 62,000-125,000 
bid (17-19)
No tobramycin Cure
Vasen, 2000 [27] 1 A. baumannii ITH 62,500à125,000
qd (21)
No No Cure
Benifla, 2004 [28] 1 A. baumannii IVT 40,000
qd (17)
No ampicillin/ 
sulbactam
Cure
Quinn, 2005 [29] 2 P. aeruginosa ITH 125,000
qd (14-16)
No No Cure
Suarez Fernandez, 
2005 [30]
7 A. baumannii IVT ITH 300,000 
bid (8-21)
Yes No 5/7 Cure
Gump, 2005 [31] 1 P. aeruginosa ITH 250,000-125,000 
qd (10)
Yes No Cure
Kasiakou, 2005 [32] 1 A. baumannii IVT 20,000 qd (21)à 
40,000 bid (42)
Yes amikacin Relapse à
Cure
Bukhary, 2005 [33] 1 A. baumannii IVT 125,000
 bid (21)
No No Cure
Sueke, 2005 [34] 1 A. baumannii ITH 75,000
bid (14)
No No Cure
Berlana, 2005 [35] 2 A. baumannii,
P. aeruginosa
ITH 125,000-250,000 
qd (8-10)
Yes No Cure
Charra, 2005 [36] 1 A. baumannii ITH 62,500-125,000
 qd (21)
No No Cure
Karakitsos, 2006 [37] 6 A. baumannii IVT 125,000-250,000 
qd (16-20)
No No Cure
Yagmur, 2006 [38] 1 P. aeruginosa ITH 62,500 
qd (21)
No No Cure
Ng, 2006 [39] 5 A. baumannii ITH IVT 62,500-125,000 
qd (3-24)
Yes amikacin 4/5 Cure
Al Shirawi, 2006 [40] 1 A. baumannii IVT 40,000 
qd (28)
No No Cure
Motaouakkil, 2006 
[41]
1 A. baumannii  ITH 62,000-125,000
qd (21)
No rifampin Cure
Schina, 2006 [42] 1 P. aeruginosa ITH 20,000-60,000
 qd (26)
Yes ceftazidime, 
amikacin
Cure
Metan, 2007 [43] 1 A. baumannii ITH 125,000
qd (21)
No meropenem Death
Enfanto, 2007 [44] 1 K. pneumoniae ITH 125,000
 qd (7)
No vancomycin, 
meropenem
Cure
Ho, 2007 [45] 1 A. baumannii ITH 80,000
qd (28)
Yes No Cure
Paramythiotou,
2007 [46]
1 A. baumannii IVT 125,000
qd (20)
Yes No Cure
Lee, 2008 [47] 1 A. baumannii IVT 62,500
qd (3)
Yes meropenem, 
sulbactam
Cure
Rodriguez 
Guardado, 2008 [48]
8 A. baumannii IVT 125,000
 bid (21)
Yes No Cure
Hachimi, 2008 [49] 1 A. baumannii IVT 62,000-125,000 
qd (22)
No amikacin Cure
Rodriguez, 2009 [50] 1 A. baumannii ITH 125,000
 qd (NR)
No rifampin Cure
Continues >>>
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Author,
year, reference Case no. Microorganisms
ITH, IVT Colistin dose (IU), 
timing, (days of treatment)
IV 
Colistin Other antibiotics
Infection 
outcome
Lopez-alvarez, 
2009 [51]
3 A. baumannii IVT 62,500-100,000
 bid (9-29)
Yes No Cure
Dalgic, 2009 [52] 1 A. baumannii IVT 12,500à125,000
 qd (20)
Yes No Cure
Baiocchi, 2010 [53] 1 P. aeruginosa ITH 125,000 
qd (NR)
No aztreonam, 
amikacin
Cure
De Pascale, 2010 [54] 1 A. baumannii  ITH 75,000-150,000 
qd (22)
Yes No Cure
Khawcharoenporn,
2010 [55]
7 A. baumannii ITH 300,000-500,000 
qd (2-21)
No imipenem, 
sulbactam, 
ciprofloxacin
5/7 Cure
Cascio, 2010 [56] 1 A. baumannii ITH 125,000
 qd (10)
No No Cure
Kim, 2010 [57] 1 A. baumannii ITH 62,500 
bid (17)
Yes rifampin Cure
Ozdemir, 2010 [58] 1 A. baumannii ITH 125,000 
qd (35)
Yes meropenem, 
sulbactam, 
amikacin
Cure
Razmkon, 2011 [59] 6 A. baumannii IVT 125,000 
qd (NR)
Yes No 3/6 Cure
Patel, 2011 [60] 1 A. baumannii IVT 125,000 
qd (36)
Yes No Cure
Saleem, 2011 [61] 5 A. baumannii ITH 4,800/kg-12,000/kg
qd (5-21)
Yes No 4/5 Cure
Alaoui, 2011 [62] 1 A. baumannii ITH 48,000
qd (NR)
Yes No Cure
Wang, 2012 [63] 4 A. baumannii IVT 25,000-200,000
bid or qd (7-27)
Yes meropenem, 
sulbactam, 
imipenem, 
3/4 Cure
Imberti, 2012 [18] 9 A. baumannii (2)
K. pneumoniae (6)
P. aeruginosa (1)
IVT 31,250-62,500 
qd – bid (11-36)
Yes
(5/9)
rifampin, 
meropenem, 
linezolid, 
sulbactam, 
amikacin, 
ceftazidime, 
fosfomycin, 
vancomycin
8/9 Cure
Ziaka, 2013 [20] 7 A. baumannii (3)
K. pneumoniae (2)
Negative cultures 
(2)
IVT 125,000 
qd (NR)
4/7 Yes NR 4/5 Cure
Karaiskos, 2013 [64] 6 A.baumannii IVT 500,000à125,000 
qdà every 48h (12-21)
Yes No Cure
Bargiacchi, 2014 [14] 3 A. baumannii (1)
K. pneumoniae (1)
P. aeruginosa (1)
IVT 250,000 qd (14-20) Yes rifampin, 
tigecycline
Cure
De Bonis, 2015 [23] 9 A. baumannii IVT 125,000-250,000 qd (14-40) Yes NR Cure
Shofty, 2016 [22] 22
(+15 ITH 
amikacin)
A. baumannii 
(51% in whole)
ITH/IVT 50,000-250,000 qd 
(median duration 9 days)
Yes NR 5/37 in 
whole Cure
Fotakopulos, 
2016 [21]
23 A. baumannii (15)
K. pneumoniae (2)
P. aeruginosa (8)
E. cloacae (1)
150,000-200,000 qd (8-24) Yes NR 20/23 Cure
Continued from previous page >>>
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the published cases and case series with IVT/ITH 
colistin [14, 18, 20-23, 24-64]. 
In a recent paper, Karaiskos and coll. proposed an 
interesting schedule of IVT administration with a 
loading dose of 500,000 IU followed by a dose of 
125,000-250,000 IU every 24h, followed by a q48h 
ITH administration after the CSF culture becomes 
negative, to reduce the risk of chemical meningitis 
or ventriculitis and the numbers of manipulations 
of the EVD [64]. However, in published studies, 
where ITH/IVT colistin was mainly used for in-
fections by A. baumannii, there was no difference 
in the cure rate and the time to CSF sterilization 
with daily ITH/IVT dosages higher or lower than 
125,000 IU. Moreover, this dosage should be high 
enough to treat even Pseudomonas aeruginosa and 
Klebsiella pneumoniae. Figure 1 shows that a cumu-
lative dose above 1,750,000 IU of ITH/IVT colistin 
(which correspond to 125,000  IU once daily for 14 
days) is associated to better outcomes. 
The duration of therapy described is quite variable, 
from one to four weeks. Shorter treatments (less 
than a week) seem to correlate with a higher mor-
tality, although in critical patients death may occur 
for other underlying conditions before the conclu-
sion of the scheduled treatment (Figure 2). By con-
verse, higher dosages may be administered in more 
severe patients, with a consistent bias toward higher 
and early mortality in those patients (Figures 3 and 
4). An important issue influencing the duration of 
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Figure 1 - Cure rate according to cu-
mulative dose of intrathecal/intraven-
tricular colistin. The cumulative dose 
of 1.750.000 correspond to 125.000 IU 
of colistin once daily (dose suggested 
by IDSA Guidelines) for 14 days.
Figure 2 - Cure rates according to du-
ration of treatment. In brackets the 
number of patients, whose duration 
of treatment was defined. 
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treatment is the time to the first negative culture 
suggesting that a fast clearance of the infection may 
result in a better outcome with an earlier chance to 
change an infected catheter or to replace the external 
catheter, an essential factor to destroy the bacterial 
biofilm adhering to the device. 
It is unclear which role IV colistin may play on 
the outcome of the CNS infection, when ITH/IVT 
colistin is used. Therefore, if the source of infec-
tion is strictly related to the colonization of the 
EVD and the infection is limited to the CNS, ITH/
IVT treatment may be sufficient to sterilize CSF, 
but if ventriculitis is the result of a bacteraemia or 
there are other sites infected, IV colistin should be 
added to ITH/IVT colistin and perhaps a second 
systemic antimicrobial, chosen according to the 
susceptibility and synergy tests [65]. 
Combination antimicrobial treatment is reported 
in many cases choosing antibiotics according to 
the susceptibility tests. Rifampin has optimal 
CNS diffusion and may have a synergistic effect 
with colistin against Gram negative bacteria, such 
as A. baumannii, P. aeruginosa and, perhaps, KPC 
[18, 41, 50, 57, 66-69]. 
Side effects are reported: seizures, controlled by 
anticonvulsant therapy (1 case), chemical menin-
gitis (5 cases), and cauda equina syndrome (1 case), 
with complete resolution after ITH administra-
tion discontinuation [39, 51, 57, 64]. No nephro-
toxicity is reported with ITH/IVT administration. 
Figure 3 - Cure rates according to 
duration of treatment and dose of 
intrathecal colistin for those patients 
whose duration and dose of treat-
ment was defined. 
Figure 4 - Cure rates according to 
dose of intrathecal/intraventricular 
colistin. In brackets the number of pa-
tients, whose duration of treatment 
was defined.
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n CONCLUSiONS
PK studies and clinical data suggest that intrave-
nous colistin alone is not sufficient to treat men-
ingitis and ventriculitis caused by Gram-negative 
multidrug resistant bacteria. Intrathecal or intra-
ventricular colistin has proved to be effective and 
safe. The suggested dose of 125,000 IU by IDSA 
Guidelines is still valid if administered once daily 
for at least 14 days. IV and IVT colistin (at least 
125,000 IU/die) for at least 10-14 days are proba-
bly required in most patients with CNS infections. 
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